Cetus Corporation

Chiron Corporation

Celera Corporation

Hoffmann-la Roche Inc.

Roche Molecular Systems, Inc.

Cetus Oncology Corporation

Alice M Wang

Kirston E Koths

Robert F Halenbeck

David F Mark

Martha B Ladner

Eric W Taylor

Janelle N Van Arsdell

Clayton L Casipit

David H Gelfand

Leo S Lin

Kit Lau

Peter Ralph

Abla A Creasey

Michael V Doyle

Thomas W Myers

Michael A Innis

Russell G Higuchi

Ze'ev Shaked

Ernest S Kawasaki

Edward Soh Smith

Mazie Yee Coyne

Charles M Rowland

Shi-da Yu Lu

Mary Kim Warren

Mary K Warren

Carita Maria Elfstrom

Nancy Jeneane Schönbrunner

Robert J Lagier

Ernest S Kaswasaki

Mazie Y Coyne

The present invention is based on the discovery of a unique 14-gene molecular prognostic signature that is useful for predicting breast cancer metastasis. In particular, the present invention relates to methods and reagents for detecting and profiling the expression levels of these genes, and methods of using the expression level information in predicting risk of breast cancer metastasis.

Molecular prognostic signature for predicting breast cancer metastasis, and uses thereof

The present invention relates to a composite metastasis score ('cMS') based on expression of a 14-gene molecular signature (referred to as a metastasis score, or 'MS') in combination with progesterone receptor (PR) expression that is useful for predicting breast cancer metastasis. In preferred embodiments, the cMS is determined by applying weighted coefficients to MS and PR. The present invention provides methods and reagents for detecting and profiling the expression levels of these genes, and methods of using the expression level information for predicting risk of breast cancer metastasis, among other embodiments.

Composite metastasis score with weighted coefficients for predicting breast cancer metastasis, and uses thereof

Molecular prognostic signature for predicting breast cancer distant metastasis, and uses thereof

The present invention relates to improved reverse transcription methods using a modified thermostable DNA polymerases, particularly in a magnesium ion buffer. These methods are particularly useful in combined reverse-transcription/amplification reactions.

High temperature reverse transcription using mutant DNA polymerases

A purified glycoprotein complex of over 1200 kD apparent native molecular weight having a sedimentation value of approtely 25S and having the ability to selectively bind human Mac-2 or interfere with PHA activation of lymphocytes, DNA sequences that encode the protein, and expression systems for expressing it, thus providing for medicaments that are useful for treating or diagnosing diseases, including cancer, infectious disease, and diseases of the immune system.

Secreted mac-2-binding glycoprotein

A purified glycoprotein complex of over 1200 kD apparent native molecular weight having a sedimentation value of approximately 25S and having the ability to selectively bind human Mac-2 or interfere with PHA activation of lymphocytes, DNA sequences that encode the protein, and expression systems for expressing it, thus providing for medicaments that are useful for treating or diagnosing diseases, including cancer, infectious disease, and diseases of the immune system.

Nucleic acid encoding secreted Mac-2 binding glycoprotein

A purified glycoprotein complex of over 1200 kD apparent native molecular weight having a sedimentation value of approximately 25S and having the ability to selectively bind human Mac-2 or interfere with PHA activation of lymphocytes, DNA sequences that encode the protein, and expression systems for expressing it, thus providing for reagents that are useful for treating or diagnosing diseases, including cancer, infectious disease, and diseases of the immune system, and for monitoring the concentration of the glycoprotein in human milk.

Secreted Mac-2-binding glycoprotein

Purified DNA sequences that encode a thermostable pyrophosphatase are provided. The purified DNA is obtained using a DNA probe consisting of SEQ ID NO: 1. Also provided are methods for producing thermostable pyrophosphatase.

Purified nucleic acid encoding a thermostable pyrophosphatase

Method for purifying secreted Mac-2-binding glycoprotein

Recombinant DNA sequences encoding the DNA polymerase activity of Pyrodictium species can be used to construct recombinant vectors and transformed host cells for production of the activity. Pyrodictium enzymes for catalyzing 3'.fwdarw.5' exonuclease activity, i.e., proofreading enzymes, are also provided. The Pyrodictium enzymes are useful in DNA amplification procedures and are not irreversibly inactivated by exposure to 100.degree. C. in a polymerase chain reaction.

Purified thermostable nucleic acid polymerase and DNA coding sequences

The present invention provides a method for determining the amount of a target acid segment in a sample by polymerase chain reaction. The method involves the simultaneous amplification or the target nucleic acid segment and an internal standard nucleic acid segment. The amount of amplified DNA from each segment is determined and compared to standard curves to determine the amount of the target nucleic acid segment present in the sample prior to amplification. The method is especially preferred for determining the quantity of a specific mRNA species in a biological sample. Additionally, an internal standard is provided useful for quantitation of multiple mRNA species.

Quantitation of nucleic acids using the polymerase chain reaction

A colony stimulating factor. CSF-1, is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein.

Recombinant colony stimulating factor-1

The present invention provides a method for determining the amount of a target acid segment in a sample by polymerase chain reaction. The method involves the simultaneous amplification of the target nucleic acid segment and an internal standard nucleic acid segment. The amount of amplified DNA from each segment is determined and compared to standard curves to determine the amount of the target nucleic acid segment present in the sample prior to amplification. The method is especially preferred for determining the quantity of a specific mRNA species in a biological sample. Additionally, an internal standard is provided useful for quantitation of multiple mRNA species.

Muteins of biologically active proteins such as IFN-.beta. and IL-2 in which cysteine residues that are not essential to biological activity have been deleted or replaced with other amino acids to eliminate sites for intermolecular crosslinking or incorrect intramolecular disulfide bridge formation. These muteins are made via bacterial expression of mutant genes that encode the muteins that have been synthesized from the genes for the parent proteins by oligonucleotide-directed mutagenesis.

Cysteine-depleted muteins of biologically active proteins

Growing community of inventors

Lafayette, CA, United States of America

Alice M Wang